- Conditions
- Malignancies, Lymphoma
- Interventions
- CS-1008 (humanized anti-DR5 antibody)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heroin Dependence, Substance-Related Disorders
- Interventions
- Buprenorphine/naloxone
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1997
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Interventions
- CS-1008, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Oklahoma City, Oklahoma
- Conditions
- Pancreatic Cancer
- Interventions
- CS-1008 (humanized anti-DR5 antibody), gemcitabine
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Fort Myers, Florida + 9 more
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
- Interventions
- Abraxane alone, Abraxane + Tigatuzumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- CS-1008, FOLFIRI
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Advanced Hepatocellular Carcinoma, Liver Cancer, Hepatic Cancer, Liver Neoplasms
- Interventions
- CS-1008 2 mg/kg, Sorafenib, CS-1008 6/2 mg/kg, CS-1008 6/6 mg/kg, CS-1008 4 mg/kg, CS-1008 6 mg/kg
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 1 more